AngioDynamics books positive Q2
AngioDynamics, a developer of medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, has reported slightly higher net income in its financial results for the fiscal 2011 second quarter, which ended Nov. 30, 2010.

Net income in the second quarter increased 5 percent to $3.3 million, compared with $3.1 million a year ago, according to the Albany, N.Y.-based company.

The net sales in the second quarter were $53.4 million, almost identical to the $53.5 million reported in the prior-year period. Also, international sales in the second quarter grew 12 percent to $6.7 million from the prior-year period.

Vascular sales were $37.5 million, a decrease of 6 percent from the second quarter a year ago. Effective for the fiscal year beginning June 1, 2010, vascular sales include both peripheral vascular and access product lines, for which the company combined the respective sales forces.

However, oncology sales increased 16 percent to $15.9 million from the prior-year second quarter, and included $1.6 million in NanoKnife system sales, up from $1.1 million in the fiscal 2011 first quarter.